Booster shot 94 percent efficient against Omicron: Sinovac

Published On 2021-12-18 11:19 GMT   |   Update On 2021-12-18 11:19 GMT

Beijing: China's biotech firm Sinovac claimed that a third dose of its Covid-19 vaccine is 94 per cent effective against the Omicron variant of the Covid-19.

This comes a day after a study found that the two doses of the vaccine failed to generate any detectable antibody response against the fast-spreading variant.

The study was conducted by the company on 20 people who received two shots and another 48 who received three shots. Seven in the first group and 45 in the second tested positive in neutralizing antibodies against the Omicron variant, the company said in a statement to the Global Times.

Sinovac said that the data demonstrated that the administration of a booster shot of its vaccine can effectively enhance the vaccine's neutralizing capacity to the Omicron variant, read the statement.

The company's findings are in contrast with those released on Tuesday in a preprint paper by the HKU researchers.

The university study also examined neutralising antibodies, one arm of immune response that serves as a rough marker for protection against infection.

Also Read:Gamaleya Center study claims Sputnik V effective against Omicron

Of 25 people who received a full two-dose course of CoronaVac, none were found to have detectable levels of neutralising antibodies, according to study author and top infectious disease expert Yuen Kwok-yung and his team.

The Omicron variant, first discovered in early November, has been reported in 77 countries and regions, according to the World Health Organization.

Also Read:Sanofi, GSK single booster dose of COVID vaccine shows strong immune responses

Tags:    
Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News